Overview

Simvastatin to Prevent SCI-Induced Bone Loss

Status:
Recruiting

Trial end date:
2021-09-30

Target enrollment:

Participant gender:

Summary

This is a double blind, randomized, placebo -controlled clinical trial with the primary goal of determining the osteogenic benefits of simvastatin in acute SCI.

Phase:

Phase 2

Details

Lead Sponsor:

Craig Hospital

Treatments:

Simvastatin